|
1
|
Löwenberg B, Downing JR and Burnett A:
Acute myeloid leukemia. N Engl J Med. 341:1051–1062. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Estey E and Döhner H: Acute myeloid
leukaemia. Lancet. 368:1894–1907. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
DiNardo CD and Cortes JE: New treatment
for acute myelogenous leukemia. Expert Opin Pharmacother.
16:95–106. 2015. View Article : Google Scholar
|
|
4
|
Vyas P, Appelbaum FR and Craddock C:
Allogeneic hematopoietic cell transplantation for acute myeloid
leukemia. Biol Blood Marrow Transplant. 21:8–15. 2015. View Article : Google Scholar
|
|
5
|
Ross DD: Novel mechanisms of drug
resistance in leukemia. Leukemia. 14:467–473. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Legrand O, Zittoun R and Marie JP: Role of
MRP1 in multidrug resistance in acute myeloid leukemia. Leukemia.
13:578–584. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Niewiarowski W, Gendaszewska E, Rebowski
G, Wójcik M, Mikołajczyk B, Goss W, Soszyński M and Bartosz G:
Multidrug resistance-associated protein - reduction of expression
in human leukaemia cells by antisense phosphorothioate
olignucleotides. Acta Biochim Pol. 47:1183–1188. 2000.
|
|
8
|
Li Z, Xie QR, Chen Z, Lu S and Xia W:
Regulation of SIRT2 levels for human non-small cell lung cancer
therapy. Lung Cancer. 82:9–15. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Harting K and Knöll B: SIRT2-mediated
protein deacetylation: An emerging key regulator in brain
physiology and pathology. Eur J Cell Biol. 89:262–269. 2010.
View Article : Google Scholar
|
|
10
|
Guarente L: Frankin H. Epstein Lecture:
Sirtuins, aging, and medicine. N Engl J Med. 364:2235–2244. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Peck B, Chen CY, Ho KK, Di Fruscia P,
Myatt SS, Coombes RC, Fuchter MJ, Hsiao CD and Lam EW: SIRT
inhibitors induce cell death and p53 acetylation through targeting
both SIRT1 and SIRT2. Mol Cancer Ther. 9:844–855. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Audrito V, Vaisitti T, Rossi D, Gottardi
D, D'Arena G, Laurenti L, Gaidano G, Malavasi F and Deaglio S:
Nicotinamide blocks proliferation and induces apoptosis of chronic
lymphocytic leukemia cells through activation of the
p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res.
71:4473–4483. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bradbury CA, Khanim FL, Hayden R, Bunce
CM, White DA, Drayson MT, Craddock C and Turner BM: Histone
deacetylases in acute myeloid leukaemia show a distinctive pattern
of expression that changes selectively in response to deacetylase
inhibitors. Leukemia. 19:1751–1759. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li L, Wang L, Li L, Wang Z, Ho Y, McDonald
T, Holyoake TL, Chen W and Bhatia R: Activation of p53 by SIRT1
inhibition enhances elimination of CML leukemia stem cells in
combination with imatinib. Cancer Cell. 21:266–281. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
North BJ and Verdin E: Interphase
nucleo-cytoplasmic shuttling and localization of SIRT2 during
mitosis. PLoS One. 2:e7842007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sunami Y, Araki M, Hironaka Y, Morishita
S, Kobayashi M, Liew EL, Edahiro Y, Tsutsui M, Ohsaka A and Komatsu
N: Inhibition of the NAD-dependent protein deacetylase SIRT2
induces granulocytic differentiation in human leukemia cells. PLoS
One. 8:e576332013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang F, Nguyen M, Qin FX and Tong Q: SIRT2
deacetylates FOXO3a in response to oxidative stress and caloric
restriction. Aging Cell. 6:505–514. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hiratsuka M, Inoue T, Toda T, Kimura N,
Shirayoshi Y, Kamitani H, Watanabe T, Ohama E, Tahimic CG, Kurimasa
A, et al: Proteomics-based identification of differentially
expressed genes in human gliomas: Down-regulation of SIRT2 gene.
Biochem Biophys Res Commun. 309:558–566. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
McGlynn LM, Zino S, MacDonald AI, Curle J,
Reilly JE, Mohammed ZM, McMillan DC, Mallon E, Payne AP, Edwards J,
et al: SIRT2: Tumour suppressor or tumour promoter in operable
breast cancer? Eur J Cancer. 50:290–301. 2014. View Article : Google Scholar
|
|
20
|
Chen J, Chan AW, To KF, Chen W, Zhang Z,
Ren J, Song C, Cheung YS, Lai PB, Cheng SH, et al: SIRT2
overexpression in hepatocellular carcinoma mediates epithelial to
mesenchymal transition by protein kinase B/glycogen synthase
kinase-3β/β-catenin signaling. Hepatology. 57:2287–2298. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jin W, Li Q, Lin Y, Lu Y, Li H, Wang L, Hu
R, Ma L, Wang J and Pang T: Reversal of Imatinib resistance in
BCR-ABL-positive leukemia after inhibition of the
Na+/H+ exchanger. Cancer Lett. 308:81–90.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kang MA, Kim MS, Kim JY, Shin YJ, Song JY
and Jeong JH: A novel pyrido-thieno-pyrimidine derivative activates
p53 through induction of phosphorylation and acetylation in
colorectal cancer cells. Int J Oncol. 46:342–350. 2015.
|
|
23
|
Konopleva M, Tari AM, Estrov Z, Harris D,
Xie Z, Zhao S, López-Berestein G and Andreeff M: Liposomal Bcl-2
antisense oligonucleotides enhance proliferation, sensitize acute
myeloid leukemia to cytosine-arabinoside, and induce apoptosis
independent of other antiapoptotic proteins. Blood. 95:3929–3938.
2000.PubMed/NCBI
|
|
24
|
Matsushita N, Takami Y, Kimura M, Tachiiri
S, Ishiai M, Nakayama T and Takata M: Role of NAD-dependent
deacetylases SIRT1 and SIRT2 in radiation and cisplatin-induced
cell death in vertebrate cells. Genes Cells. 10:321–332. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vaquero A, Scher M, Lee D,
Erdjument-Bromage H, Tempst P and Reinberg D: Human SirT1 interacts
with histone H1 and promotes formation of facultative
heterochromatin. Mol Cell. 16:93–105. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yeung F, Hoberg JE, Ramsey CS, Keller MD,
Jones DR, Frye RA and Mayo MW: Modulation of NF-kappaB-dependent
transcription and cell survival by the SIRT1 deacetylase. EMBO J.
23:2369–2380. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nakagawa T and Guarente L: Sirtuins at a
glance. J Cell Sci. 124:833–838. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
North BJ and Verdin E: Mitotic regulation
of SIRT2 by cyclin-dependent kinase 1-dependent phosphorylation. J
Biol Chem. 282:19546–19555. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dan L, Klimenkova O, Klimiankou M, Klusman
JH, van den Heuvel-Eibrink MM, Reinhardt D, Welte K and Skokowa J:
The role of sirtuin 2 activation by nicotinamide
phosphoribosyl-transferase in the aberrant proliferation and
survival of myeloid leukemia cells. Haematologica. 97:551–559.
2012. View Article : Google Scholar :
|
|
30
|
Vousden KH and Lane DP: p53 in health and
disease. Nat Rev Mol Cell Biol. 8:275–283. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Moll UM, Wolff S, Speidel D and Deppert W:
Transcription-independent pro-apoptotic functions of p53. Curr Opin
Cell Biol. 17:631–636. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cory S and Adams JM: The Bcl2 family:
Regulators of the cellular life-or-death switch. Nat Rev Cancer.
2:647–656. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Komarov PG, Komarova EA, Kondratov RV,
Christov-Tselkov K, Coon JS, Chernov MV and Gudkov AV: A chemical
inhibitor of p53 that protects mice from the side effects of cancer
therapy. Science. 285:1733–1737. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ali I, Damdimopoulou P, Stenius U and
Halldin K: Cadmium at nanomolar concentrations activates
Raf-MEK-ERK1/2 MAPKs signaling via EGFR in human cancer cell lines.
Chem Biol Interact. 231:44–52. 2015. View Article : Google Scholar : PubMed/NCBI
|
